Other languages Talphera, Inc.

Equities

TLPH

US00444T2096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
0.92 ^USD	+0.40%		+10.84%	+25.17%

May. 14	Talphera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 14	Transcript : Talphera, Inc., Q1 2024 Earnings Call, May 14, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Talphera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14
Talphera, Inc. Appoints Dr. Shakil Aslam as Chief Development Officer, Effective May 20, 2024	May. 14
Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06
Talphera, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06
Talphera, Inc. Announces Management Changes	Mar. 01
Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director	Jan. 22
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million	Jan. 18
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	Jan. 17
AcelRx Pharmaceuticals, Inc. will Change its Ticker to TLPH from ACRX	Jan. 10
Talphera Expects to Initiate the Registrational Study of Niyad	Jan. 09
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 08
AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study	23-10-03
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
Vertical Pharmaceuticals, LLC acquired DSUVIA from AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) for $119.2 million.	23-04-02
AcelRx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30
AcelRx Pharmaceuticals Q4 Loss Narrows After Sales Jump	23-03-30
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-30
AcelRx Selling Dsuvia to Alora Pharmaceuticals; Shares Rise	23-03-14
AcelRx Pharmaceuticals, Inc. Announces Peer-Reviewed Publication on the Use of Dsuvia(R) for in Office Rhinology Procedures	23-03-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Talphera, Inc.

Equities

TLPH

US00444T2096

Other languages

Filters